ALKOVE-1 (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if a new experimental drug called NVL-655 (the study drug) is a beneficial option for people with NSCLC.
Advanced Non-Small Cell Lung Cancer (NSCLC)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with advanced NSCLC
- Are positive for the ALK gene
For more information about who can be in this study, please contact the study team at annmarie.peters@dm.duke.edu.
What is Involved?
This study has 2 parts, a screening period and a study dosing period.
If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you’re eligible for the dosing period
If you’re eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive the study drug
The study drug is given as an infusion into a vein (IV) every 3 weeks. Different doses of the study drug are being tested in this study. The dose of NVL-655 you receive will depend on when you enter the study. You will continue to receive the study drug for as long as you and the study doctor believe that you are receiving a benefit from it.
Study Details
